Matches in Wikidata for { <http://www.wikidata.org/entity/Q94146349> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q94146349 description "article scientifique publié en 2018" @default.
- Q94146349 description "wetenschappelijk artikel" @default.
- Q94146349 description "наукова стаття" @default.
- Q94146349 name "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 name "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 type Item @default.
- Q94146349 label "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 label "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 prefLabel "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 prefLabel "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 P1433 Q94146349-276647C3-57E8-4494-82F3-38B989D4138E @default.
- Q94146349 P1476 Q94146349-70C46D1A-D8D2-46C5-A338-A0602C5D567B @default.
- Q94146349 P2093 Q94146349-423AC1E5-DE93-46D2-A333-18342806A805 @default.
- Q94146349 P2093 Q94146349-46118AD5-8573-460C-8E52-1C5A0506ED09 @default.
- Q94146349 P2093 Q94146349-656151DE-8F1E-413C-B226-22D99405066F @default.
- Q94146349 P2093 Q94146349-6623DD36-ABFA-4B82-913A-97E226086A27 @default.
- Q94146349 P2093 Q94146349-672B4344-9ACF-4925-9783-9B5C60160636 @default.
- Q94146349 P2093 Q94146349-6F8FDA14-C9F2-4E3D-8F33-1903F12286F5 @default.
- Q94146349 P2093 Q94146349-76308B01-77A3-4A3C-8A10-CD834698B473 @default.
- Q94146349 P2093 Q94146349-82EF6462-CE09-4620-819C-C0BA8D27D4C2 @default.
- Q94146349 P2093 Q94146349-8DCFFCEE-4446-466C-B34B-AC7AC42BFBC6 @default.
- Q94146349 P2093 Q94146349-957ABF14-9102-44E9-9673-A51166474FF0 @default.
- Q94146349 P2093 Q94146349-977C8D72-5D01-49B6-BEC2-C89934A991B3 @default.
- Q94146349 P2093 Q94146349-A9184F22-941A-43BE-AEC9-ABC73FE5CA67 @default.
- Q94146349 P2093 Q94146349-BCB7EBA9-A5A4-43E3-BB1A-B7047CA1BBDF @default.
- Q94146349 P2093 Q94146349-D9FD165B-EE97-4FD2-828B-F560D1EBE384 @default.
- Q94146349 P2093 Q94146349-DBE4E503-0FBF-4365-9EEC-94B8A58F6896 @default.
- Q94146349 P2093 Q94146349-EE3F607F-6E4E-4B69-920F-2F9D44433F70 @default.
- Q94146349 P304 Q94146349-72DB3EC3-4016-43E6-9440-E4EDCB02FE8C @default.
- Q94146349 P31 Q94146349-22FB19F2-DC66-4A2F-A61F-03B481FFBFD4 @default.
- Q94146349 P356 Q94146349-389F9BCB-CA30-4D30-A289-FC0DC9DE4673 @default.
- Q94146349 P433 Q94146349-4C559B97-F6E2-4D5D-8C38-9FA238E4CA55 @default.
- Q94146349 P478 Q94146349-408F4B76-D6D9-4185-9089-25C315DC210D @default.
- Q94146349 P50 Q94146349-8269E464-F210-4C06-B458-0B30F3337B92 @default.
- Q94146349 P577 Q94146349-03E7F019-9A25-4E9C-B456-6278A318F01D @default.
- Q94146349 P921 Q94146349-0F0AC9B3-F08A-4D1E-B281-4EF65A4A73FA @default.
- Q94146349 P921 Q94146349-B847B822-F766-4724-B786-76D23E4F44B7 @default.
- Q94146349 P932 Q94146349-5DCCF315-3F48-4D5B-9CD3-E3A8094010A6 @default.
- Q94146349 P356 NOY148.048 @default.
- Q94146349 P1433 Q15724471 @default.
- Q94146349 P1476 "ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM" @default.
- Q94146349 P2093 "Arati Desai" @default.
- Q94146349 P2093 "Brian Alexander" @default.
- Q94146349 P2093 "David Peereboom" @default.
- Q94146349 P2093 "Jeffrey Supko" @default.
- Q94146349 P2093 "Jorg Dietrich" @default.
- Q94146349 P2093 "Joy Fisher" @default.
- Q94146349 P2093 "Keith Ligon" @default.
- Q94146349 P2093 "L Burt Nabors" @default.
- Q94146349 P2093 "Manmeet Ahluwalia" @default.
- Q94146349 P2093 "Megan Sims" @default.
- Q94146349 P2093 "Naoko Takebe" @default.
- Q94146349 P2093 "Nathalie Agar" @default.
- Q94146349 P2093 "Serena Desideri" @default.
- Q94146349 P2093 "Stuart Grossman" @default.
- Q94146349 P2093 "Thomas Kaley" @default.
- Q94146349 P2093 "Xiaobu Ye" @default.
- Q94146349 P304 "vi13-vi14" @default.
- Q94146349 P31 Q13442814 @default.
- Q94146349 P356 "10.1093/NEUONC/NOY148.048" @default.
- Q94146349 P433 "Suppl 6" @default.
- Q94146349 P478 "20" @default.
- Q94146349 P50 Q105531697 @default.
- Q94146349 P577 "2018-11-05T00:00:00Z" @default.
- Q94146349 P921 Q282142 @default.
- Q94146349 P921 Q425088 @default.
- Q94146349 P932 "6216169" @default.